Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972152 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
A Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01972152: Completed Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
NCT01972152 is a Phase 2 study of Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 30 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01972152, a Phase 2 study of Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
Primary Outcome
Number of serious adverse events (SAEs) per treatment group
Conditions Studied
Interventions
- DRUG G-Pen(TM) 1 mg
- DRUG Lilly Glucagon(TM) 1 mg
- DRUG G-Pen(TM) 0.5 mg
Study Locations (1)
Texas
- Texas Diabetes Institute, University Health System - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01972152 record still lists
NCT01972152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 3 interventions - of which G-Pen(TM) 1 mg is the first listed.
NCT01972152 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01972152 about?
NCT01972152 is a clinical study titled "Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia". The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
What is the current status of trial NCT01972152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-10. Estimated completion is 2014-02.
What conditions does trial NCT01972152 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT01972152?
The interventions under investigation include: G-Pen(TM) 1 mg (DRUG), Lilly Glucagon(TM) 1 mg (DRUG), G-Pen(TM) 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT01972152?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01972152 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01972152's enrollment target sits among peer trials
30 23rd of 40 higher than 17 of 40 other Hypoglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
COMPLETED · Phase 2
-
G-Pen™ for Hypoglycemia Rescue in T1D Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia